Overall, this study and future work with mouse models should help shed more light on the real potential of new combinational therapy in nanomedicine using ATO as a PARP-1 inhibitor with DNA-damaging drugs for treatment of multiple drug resistant cancers. This evidence concerns the gene PARP1 and cancer.